Abstract
Reverse-phase protein array (RPPA) technology is a high-throughput antibody- and microarray-based approach for the rapid profiling of levels of proteins and protein posttranslational modifications in biological specimens. The technology consumes small amounts of samples, can sensitively detect low-abundance proteins and posttranslational modifications, enables measurements of multiple signaling pathways in parallel, has the capacity to analyze large sample numbers, and offers robust interexperimental reproducibility. These features of RPPA experiments have motivated and enabled the use of RPPA technology in various biomedical, translational, and clinical applications, including the delineation of molecular mechanisms of disease, profiling of druggable signaling pathway activation, and search for new prognostic markers. Owing to the complexity of many of these applications, such as developing multiplex protein assays for diagnostic laboratories or integrating posttranslational modification-level data using large-scale proteogenomic approaches, robust and well-validated data are essential. There are many distinct components of an RPPA workflow, and numerous possible technical setups and analysis parameter options exist. The differences between RPPA platform setups around the world offer opportunities to assess and minimize interplatform variation. Crossplatform validation may also aid in the evaluation of robust, platform-independent protein markers of disease and response to therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Akbani R, Becker KF, Carragher N et al (2014a) Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (reverse phase protein array) society. Mol Cell Proteomics 13:1625–1643. https://doi.org/10.1074/mcp.O113.034918
Akbani R, Ng PK, Werner HM et al (2014b) A pan-cancer proteomic perspective on the Cancer Genome Atlas. Nat Commun 5:3887. https://doi.org/10.1038/ncomms4887
Ali M, Khan SA, Wennerberg K, Aittokallio T (2018) Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach. Bioinformatics 34:1353–1362. https://doi.org/10.1093/bioinformatics/btx766
Anderson T, Wulfkuhle J, Liotta L et al (2009) Improved reproducibility of reverse-phase protein microarrays using array microenvironment normalization. Proteomics 9:5562–5566. https://doi.org/10.1002/pmic.200900505
Aslan O, Cremona M, Morgan C et al (2018) Preclinical evaluation and reverse phase protein array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. BMC Cancer 18:168. https://doi.org/10.1186/s12885-018-4035-0
Austin J, Holway AH (2011) Contact printing of protein microarrays. Methods Mol Biol 785:379–394. https://doi.org/10.1007/978-1-61779-286-1_25
Baldelli E, Calvert V, Hodge A et al (2017) Reverse phase protein microarrays. Methods Mol Biol 1606:149–169. https://doi.org/10.1007/978-1-4939-6990-6_11
Bernhardt S, Bayerlová M, Vetter M et al (2017) Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Breast Cancer Res 19:112. https://doi.org/10.1186/s13058-017-0905-7
Bernhardt S, Tönsing C, Mitra D et al (2019) Functional proteomics of breast cancer metabolism identifies GLUL as responder during hypoxic adaptation. J Proteome Res 18:1352–1362. https://doi.org/10.1021/acs.jproteome.8b00944
Boellner S, Becker KF (2015) Reverse phase protein arrays—quantitative assessment of multiple biomarkers in biopsies for clinical use. Microarrays (Basel) 4:98–114. https://doi.org/10.3390/microarrays4020098
Byron A (2017) Clustering and network analysis of reverse phase protein array data. Methods Mol Biol 1606:171–191. https://doi.org/10.1007/978-1-4939-6990-6_12
Byron A, Bernhardt S, Ouine B et al (2019) Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies. bioRxiv 769158. https://doi.org/10.1101/769158
Celis JE, Moreira JM, Gromova I et al (2005) Towards discovery-driven translational research in breast cancer. FEBS J 272:2–5. https://doi.org/10.1111/j.1432-1033.2004.04418.x
Chebouba L, Miannay B, Boughaci D, Guziolowski C (2018) Discriminate the response of acute myeloid leukemia patients to treatment by using proteomics data and answer set programming. BMC Bioinformatics 19:59. https://doi.org/10.1186/s12859-018-2034-4
Coarfa C, Fiskus W, Eedunuri VK et al (2016) Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of micro RNAs suppressed in metastatic prostate cancer. Oncogene 35:2345–2356. https://doi.org/10.1038/onc.2015.295
Creighton CJ, Huang S (2015) Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Des Devel Ther 9:3519–3527. https://doi.org/10.2147/DDDT.S38375
Dincer C, Bruch R, Kling A et al (2017) Multiplexed point-of-care testing - xPOCT. Trends Biotechnol 35:728–742. https://doi.org/10.1016/j.tibtech.2017.03.013
Ding L, Bailey MH, Porta-Pardo E et al (2018) Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 173:305–320.e10. https://doi.org/10.1016/j.cell.2018.03.033
Edfors F, Hober A, Linderbäck K et al (2018) Enhanced validation of antibodies for research applications. Nat Commun 9:4130. https://doi.org/10.1038/s41467-018-06642-y
Eichner J, Heubach Y, Ruff M et al (2014) RPPApipe: a pipeline for the analysis of reverse-phase protein array data. Biosystems 122:19–24. https://doi.org/10.1016/j.biosystems.2014.06.009
Ellington AA, Kullo IJ, Bailey KR, Klee GG (2010) Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 56:186–193. https://doi.org/10.1373/clinchem.2009.127514
Faham N, Zhao L, Welm AL (2018) mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. NPJ Breast Cancer 4:36. https://doi.org/10.1038/s41523-018-0091-5
Fallahi-Sichani M, Moerke NJ, Niepel M et al (2015) Systematic analysis of BRAF (V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. Mol Syst Biol 11:797. https://doi.org/10.15252/msb.20145877
Gallagher RI, Espina V (2014) Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther 18:619–630. https://doi.org/10.1007/s40291-014-0122-3
Girotti MR, Lopes F, Preece N et al (2015) Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27:85–96. https://doi.org/10.1016/j.ccell.2014.11.006
Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F et al (2011) Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8:11. https://doi.org/10.1186/1559-0275-8-11
Goodman SL (2018) The path to VICTORy - a beginner’s guide to success using commercial research antibodies. J Cell Sci 131:jcs216416. https://doi.org/10.1242/jcs.216416
Grubb RL, Calvert VS, Wulkuhle JD et al (2003) Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3:2142–2146. https://doi.org/10.1002/pmic.200300598
Grubb RL, Deng J, Pinto PA et al (2009) Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res 8:3044–3054. https://doi.org/10.1021/pr8009337
Gujral TS, Karp RL, Finski A et al (2013) Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene 32:3470–3476. https://doi.org/10.1038/onc.2012.378
Guo H, Liu W, Ju Z et al (2012) An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 10:56. https://doi.org/10.1186/1477-5956-10-56
Haab BB (2005) Antibody arrays in cancer research. Mol Cell Proteomics 4:377–383. https://doi.org/10.1074/mcp.M500010-MCP200
Hayashi N, Manyam GC, Gonzalez-Angulo AM et al (2014) Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. Oncologist 19:909–914. https://doi.org/10.1634/theoncologist.2014-0099
Henjes F, Bender C, von der Heyde S et al (2012) Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogene 1:e16. https://doi.org/10.1038/oncsis.2012.16
Hennessy BT, Lu Y, Gonzalez-Angulo AM et al (2010) A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6:129–151. https://doi.org/10.1007/s12014-010-9055-y
Hoadley KA, Yau C, Hinoue T et al (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173:291–304.e6. https://doi.org/10.1016/j.cell.2018.03.022
Hsieh HJ, Zhang W, Lin SH et al (2018) Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun 9:3982. https://doi.org/10.1038/s41467-018-05639-x
Hu J, He X, Baggerly KA et al (2007) Non-parametric quantification of protein lysate arrays. Bioinformatics 23:1986–1994. https://doi.org/10.1093/bioinformatics/btm283
Hutter G, Sailer M, Azad TD et al (2017) Reverse phase protein arrays enable glioblastoma molecular subtyping. J Neuro-Oncol 131:437–448. https://doi.org/10.1007/s11060-016-2316-5
Improta G, Zupa A, Fillmore H et al (2011) Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res 10:3089–3097. https://doi.org/10.1021/pr200065t
Jiang R, Mircean C, Shmulevich I et al (2006) Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6:2964–2971. https://doi.org/10.1002/pmic.200500555
Ju Z, Liu W, Roebuck PL et al (2015) Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics 31:912–918. https://doi.org/10.1093/bioinformatics/btu736
Kaushik P, Molinelli EJ, Miller ML et al (2014) Spatial normalization of reverse phase protein array data. PLoS One 9:e97213. https://doi.org/10.1371/journal.pone.0097213
Kearney P, Boniface JJ, Price ND, Hood L (2018) The building blocks of successful translation of proteomics to the clinic. Curr Opin Biotechnol 51:123–129. https://doi.org/10.1016/j.copbio.2017.12.011
Kingsmore SF (2006) Nat Rev Drug Discov 5:310–320. https://doi.org/10.1038/nrd2006
Koch RJ, Barrette AM, Stern AD et al (2018) Validating antibodies for quantitative western blot measurements with microwestern array. Sci Rep 8:11329. https://doi.org/10.1038/s41598-018-29436-0
Li B, Liang F, Hu J, He AX (2012) Reno: regularized non-parametric analysis of protein lysate array data. Bioinformatics 28:1223–1229. https://doi.org/10.1093/bioinformatics/bts131
Li J, Zhao W, Akbani R et al (2017) Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225–239. https://doi.org/10.1016/j.ccell.2017.01.005
Lièvre A, Ouine B, Canet J et al (2017) Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. Br J Cancer 117:1819–1827. https://doi.org/10.1038/bjc.2017.353
Ling MM, Ricks C, Lea P (2007) Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn 7:87–98. https://doi.org/10.1586/14737159.7.1.87
List M, Block I, Pedersen ML et al (2014) Microarray R-based analysis of complex lysate experiments with MIRACLE. Bioinformatics 30:i631–i638. https://doi.org/10.1093/bioinformatics/btu473
Liu W, Ju Z, Lu Y et al (2014) A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. Cancer Inform 13:109–117. https://doi.org/10.4137/CIN.S13329
Lubbock ALR, Stewart GD, O’Mahony FC et al (2017) Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Med 15:118. https://doi.org/10.1186/s12916-017-0874-9
Macleod KG, Serrels B, Carragher NO (2017) Reverse phase protein arrays and drug discovery. Methods Mol Biol 1647:153–169. https://doi.org/10.1007/978-1-4939-7201-2_10
Mannsperger H, Uhlmann S, Korf U, Sahin O (2011) Utilization of RNAi to validate antibodies for reverse phase protein arrays. Methods Mol Biol 785:45–54. https://doi.org/10.1007/978-1-61779-286-1_4
Master SR, Bierl C, Kricka LJ (2006) Diagnostic challenges for multiplexed protein microarrays. Drug Discov Today 11:1007–1011. https://doi.org/10.1016/j.drudis.2006.09.010
Masuda M, Yamada T (2015) Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine. Biochim Biophys Acta 1854:651–657. https://doi.org/10.1016/j.bbapap.2014.10.014
McWilliam I, Chong Kwan M, Hall D (2011) Inkjet printing for the production of protein microarrays. Methods Mol Biol 785:345–361. https://doi.org/10.1007/978-1-61779-286-1_23
Mircean C, Shmulevich I, Cogdell D et al (2005) Robust estimation of protein expression ratios with lysate microarray technology. Bioinformatics 21:1935–1942. https://doi.org/10.1093/bioinformatics/bti258
Mitra R, Mueller P, Ji Y et al (2012) Sparse Bayesian graphical models for RPPA time course data. IEEE Int Workshop Genomic Signal Process Stat 2012:113–117. https://doi.org/10.1109/GENSIPS.2012.6507742
Mujawar LH, Norde W, van Amerongen A (2013) Spot morphology of non-contact printed protein molecules on non-porous substrates with a range of hydrophobicities. Analyst 138:518–524. https://doi.org/10.1039/c2an36104c
Murakoshi Y, Honda K, Sasazuki S et al (2011) Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci 102:630–638. https://doi.org/10.1111/j.1349-7006.2010.01818.x
Neeley ES, Kornblau SM, Coombes KR, Baggerly KA (2009) Variable slope normalization of reverse phase protein arrays. Bioinformatics 25:1384–1389. https://doi.org/10.1093/bioinformatics/btp174
Neeley ES, Baggerly KA, Kornblau SM (2012) Surface adjustment of reverse phase protein arrays using positive control spots. Cancer Inform 11:77–86. https://doi.org/10.4137/CIN.S9055
Nishizuka SS, Mills GB (2016) New era of integrated cancer biomarker discovery using reverse-phase protein arrays. Drug Metab Pharmacokinet 31:35–45. https://doi.org/10.1016/j.dmpk.2015.11.009
Nishizuka S, Charboneau L, Young L et al (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100:14229–14234. https://doi.org/10.1073/pnas.2331323100
Noren DP, Long BL, Norel R et al (2016) A crowdsourcing approach to developing and assessing prediction algorithms for AML prognosis. PLoS Comput Biol 12:e1004890. https://doi.org/10.1371/journal.pcbi.1004890
O’Farrell AC, Miller IS, Evans R et al (2019) Implementing reverse phase protein array profiling as a sensitive method for the early pre-clinical detection of off-target toxicities associated with sunitinib malate. Proteomics Clin Appl 13:e1800159. https://doi.org/10.1002/prca.201800159
Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–1989. https://doi.org/10.1038/sj.onc.1204265
Pawlak M, Carragher NO (2017) Reverse phase protein arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. Drug Discov Today Technol 23:7–16. https://doi.org/10.1016/j.ddtec.2017.05.002
Pawlak M, Schick E, Bopp MA et al (2002) Zeptosens’ protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics 2:383–393
Peng H, Peng T, Wen J et al (2014) Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach. Bioinformatics 30:1899–1907. https://doi.org/10.1093/bioinformatics/btu133
Pierobon M, Silvestri A, Spira A et al (2014) Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J Proteome Res 13:2846–2855. https://doi.org/10.1021/pr401267m
Pierobon M, Ramos C, Wong S et al (2017) Enrichment of PI3K-AKT-mTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res 23:4919–4928. https://doi.org/10.1158/1078-0432.CCR-16-2656
Pin E, Federici G, Petricoin EF 3rd (2014) Preparation and use of reverse protein microarrays. Curr Protoc Protein Sci 75:Unit 27.7. https://doi.org/10.1002/0471140864.ps2707s75
Rodland KD, Piehowski P, Smith RD (2018) Moonshot objectives: catalyze new scientific breakthroughs—proteogenomics. Cancer J 24:121–125. https://doi.org/10.1097/PPO.0000000000000315
Rodriguez H, Pennington SR (2018) Revolutionizing precision oncology through collaborative proteogenomics and data sharing. Cell 173:535–539. https://doi.org/10.1016/j.cell.2018.04.008
Rudelius M, Pittaluga S, Nishizuka S et al (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108:1668–1676. https://doi.org/10.1182/blood-2006-04-015586
Sandhu C, Qureshi A, Emili A (2018) Panomics for precision medicine. Trends Mol Med 24:85–101. https://doi.org/10.1016/j.molmed.2017.11.001
Sheehan KM, Calvert VS, Kay EW et al (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4:346–355. https://doi.org/10.1074/mcp.T500003-MCP200
Sikorski K, Mehta A, Inngjerdingen M et al (2018) A high-throughput pipeline for validation of antibodies. Nat Methods 15:909–912. https://doi.org/10.1038/s41592-018-0179-8
Spurrier B, Honkanen P, Holway A et al (2008) Protein and lysate array technologies in cancer research. Biotechnol Adv 26:361–369. https://doi.org/10.1016/j.biotechadv.2008.04.002
Stillman BA, Tonkinson JL (2000) FAST slides: a novel surface for microarrays. BioTechniques 29:630–635. https://doi.org/10.2144/00293pf01
Sun M, Lai D, Zhang L, Huang X (2015) Modified SuperCurve method for analysis of reverse-phase protein array data. J Comput Biol 22:765–769. https://doi.org/10.1089/cmb.2015.0007
Tabus I, Hategan A, Mircean C et al (2006) Nonlinear modeling of protein expressions in protein arrays. IEEE Trans Signal Process 54:2394–2407. https://doi.org/10.1109/TSP.2006.873719
Teo K, Gómez-Cuadrado L, Tenhagen M et al (2018) E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Sci Rep 8:15454. https://doi.org/10.1038/s41598-018-33525-5
Tibes R, Qiu Y, Lu Y et al (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5:2512–2521. https://doi.org/10.1158/1535-7163.MCT-06-0334
Troncale S, Barbet A, Coulibaly L et al (2012) NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data. PLoS One 7:e38686. https://doi.org/10.1371/journal.pone.0038686
Uhlen M, Bandrowski A, Carr S et al (2016) A proposal for validation of antibodies. Nat Methods 13:823–827. https://doi.org/10.1038/nmeth.3995
Ummanni R, Mannsperger HA, Sonntag J et al (2014) Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery. Biochim Biophys Acta 1844:950–959. https://doi.org/10.1016/j.bbapap.2013.11.017
van Oostrum J, Calonder C, Rechsteiner D et al (2009) Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin Appl 3:412–422. https://doi.org/10.1002/prca.200800070
Voskuil JL (2017) The challenges with the validation of research antibodies. F1000Res 6: 161. https://doi.org/10.12688/f1000research.10851.1
Wachter A, Bernhardt S, Beissbarth T, Korf U (2015) Analysis of reverse phase protein array data: from experimental design towards targeted biomarker discovery. Microarrays (Basel) 4:520–539. https://doi.org/10.3390/microarrays4040520
Wang J, Zhao W, Guo H et al (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742. https://doi.org/10.1186/s12885-018-4654-5
Wilson DS, Nock S (2003) Recent developments in protein microarray technology. Angew Chem Int Ed Engl 42:494–500. https://doi.org/10.1002/anie.200390150
Wulfkuhle JD, Aquino JA, Calvert VS et al (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3:2085–2090. https://doi.org/10.1002/pmic.200300591
Wulfkuhle JD, Spira A, Edmiston KH, Petricoin EF 3rd (2017) Innovations in clinical trial design in the era of molecular profiling. Methods Mol Biol 1606:19–36. https://doi.org/10.1007/978-1-4939-6990-6_2
Yang CR, Tongyoo P, Emamian M et al (2015) Deep proteomic profiling of vasopressin-sensitive collecting duct cells. I. Virtual Western blots and molecular weight distributions. Am J Physiol Cell Physiol 309:C785–C798. https://doi.org/10.1152/ajpcell.00213.2015
Zhang L, Wei Q, Mao L et al (2009) Serial dilution curve: a new method for analysis of reverse phase protein array data. Bioinformatics 25:650–654. https://doi.org/10.1093/bioinformatics/btn663
Zong Y, Zhang S, Chen HT et al (2007) Forward-phase and reverse-phase protein microarray. Methods Mol Biol 381:363–374. https://doi.org/10.1007/978-1-59745-303-5_18
Acknowledgments
R. Akbani, S. Bernhardt, N.O. Carragher, A. Cartier, L. de Koning, U. Korf, K.G. Macleod, B. Ouine, B. Serrels, and V. Sibut are acknowledged for discussions about or analyses using multiple RPPA platforms. A.B. was funded by Cancer Research UK.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Byron, A. (2019). Reproducibility and Crossplatform Validation of Reverse-Phase Protein Array Data. In: Yamada, T., Nishizuka, S., Mills, G., Liotta, L. (eds) Reverse Phase Protein Arrays. Advances in Experimental Medicine and Biology, vol 1188. Springer, Singapore. https://doi.org/10.1007/978-981-32-9755-5_10
Download citation
DOI: https://doi.org/10.1007/978-981-32-9755-5_10
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9754-8
Online ISBN: 978-981-32-9755-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)